摘要
目的观察亚甲基四氢叶酸还原酶(MTHFR)C667T基因多态性与5-氟尿嘧啶(5-FU)为基础的化疗方案治疗晚期胃癌的疗效间的关系。方法收集经病理学确诊的晚期胃癌59例。所有病例化疗前抽取外周静脉血,提取DNA,用连接酶检测反应技术(LDR)检测研究对象的MTHFR基因型。所有患者经5-FU为基础的联合化疗方案化疗。结果 59例晚期胃癌患者中,21例(35.59%)为MTHFRC/C基因型,22例(37.29%)为MTHFRC/T基因型,16例(27.12%)为MTHFRT/T基因型。其中,4例CR,14例PR,19例SD,22例PD,总有效率为30.51%(18/59)。MTHFRT/T基因型患者的化疗有效率(68.75%)明显高于C/T基因型患者(18.18%)(P<0.01),也明显高于C/C基因型(14.29%)(P<0.01)。结论 MTHFR基因型对预测以5-FU为基础化疗方案治疗晚期胃癌的疗效具有较好的临床意义。
Objective To investigate the relationship between the methylenetetrahydrofolate reductase（MTHFR） polymorphism and the response to 5-fluoropyrimidine（FU）-based chemotherapy in advanced gastric cancer（AGC）.Methods DNAs of peripheral blood leukocytes from 59 patients with AGC were obtained before therapy and analyzed for MTHFR genotypes by PCR-LDR method.All patients were treated with 5-FU-based chemotherapy.Results Of 59 AGC cases with MTHFR C677T genotype,the frequency of C/C was 35.59%,C/T was 37.79% and T/T was 27.12%.Total response rate of chemotherapy was 30.51%,including 4 patients with complete response,14 with partial response,19 with stable disease and 22 with progressive disease.However,the response rate in patients with T/T genotype （68.75%） was significantly higher than either the patients with C/T genotype（18.18%） （P0.01） or with C/C genotype（14.29%）（P0.01）.Conclusion MTHFR C677T polymorphism can predict the effects of 5-FU-based chemotherapy in AGC.
出处
《江苏医药》
CAS
CSCD
北大核心
2010年第18期2125-2127,共3页
Jiangsu Medical Journal
基金
常州市卫生局重大招标课题(ZD200810)
关键词
晚期胃癌
亚甲基四氢叶酸还原酶
5-氟尿嘧啶
Advanced gastric cancer
Methylenetetrahydrofolate reductase
5-fluoropyrimidine
